Nadag, SiReen merging

Drug discovery companies Nadag (Munich, Germany) and SiReen (Munich, Germany) will merge to form Sirenade Pharmaceuticals, which will focus on CNS and oncology indications. The new company will combine SiReen's biological and structural kinase discovery platform with Nadag's chemical kinase platform for hit and lead generation.

Nadag has one preclinical Alzheimer's disease (AD) program, and SiReen has two oncology programs in lead development. The new company will exercise options from an undisclosed company to in-license two compounds in Phase I/II studies, Sirenade 001 to treat AD and Parkinson's disease (PD) and to prevent migraine, and Sirenade 002 to treat acute migraine pain. ...